Top

Published in:

01-06-2011 | Original Research Paper

Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor β1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation

Authors: Remina Ikeda, Kyoko Ishii, Yoshiko Hoshikawa, Junya Azumi, Yuta Arakaki, Toshihiro Yasui, Shizuka Matsuura, Yoshiaki Matsumi, Yohei Kono, Yusuke Mizuta, Akihiro Kurimasa, Ichiro Hisatome, Scott L. Friedman, Hironaka Kawasaki, Goshi Shiota

Published in: Inflammation Research | Issue 6/2011

Abstract

Objective and design

To clarify the molecular mechanism of polyenylphosphatidylcholine (PPC), we examined the involvement of reactive oxygen species (ROS) and NADPH oxidase 4 (Nox4) in human hepatic stellate cells (HSCs).

Material

Using human LX-2 HSC cells, we examined the effects of PPC on expression of α-smooth muscle actin (α-SMA) and collagen 1, generation of ROS, Nox4 expression, p38 activation and cell proliferation, induced by transforming growth factor β1 (TGFβ1).

Results

PPC suppressed ROS which are induced by TGFβ1, phosphorylation of p38MAPK, and expression levels of α-SMA and collagen 1 in a dose-dependent manner. Higher concentrations of PPC also suppressed Nox4 levels.

Conclusion

These results suggest that ROS and Nox4 induced by TGFβ1 are the therapeutic targets of PPC in the suppression of human hepatic stellate cell activation.

Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroeterology. 2008;134:1655–69.CrossRef

Proell MMV, Fischer ANM, Mikulits W. Activation of hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-β dependent fashion. J Cell Physiol. 2006;209:560–7.PubMedCrossRef

Cavin LG, Romieu-Mourez R, Panta GR, Sun J, Factor VM, Thorgeirsson SS, Sonenshein GE, Arsura M. Inhibition of CK2 activity by TGF-β1 promotes IκB-α protein stabilization and apoptosis of immortalized hepatocytes. Hepatology. 2003;38:1540–51.PubMed

Yanagitani A, Yamada S, Yasui S, Shimomura T, Murai R, Shiota G. Retinoic acid receptor α dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology. 2004;40:366–75.PubMedCrossRef

Aleynik SI, Leo MA, Ma X, Aleynik MK, Lieber CS. Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J Hepatol. 1997;27:554–61.PubMedCrossRef

Lieber CS, Robins SJ, DeCarli LM, Mak KM, Fasulo JM, Leo MA. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology. 1994;106:152–9.PubMed

Lieber CS, Leo MA, Aleynik LSI. Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcohol Clin Exp Res. 1997;21:375–9.PubMedCrossRef

Brady LM, Fox ES, Fimmel CJ. Polyenylphosphadidylcholine inhibits PDGF-induced proliferation in rat hepatic stellate cells. Biochem Biophys Res Commun. 1998;248:174–9.PubMedCrossRef

Cao Q, Mak KM, Lieber CS. DLPC decreases TGF-β1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastroenterol Liver Physiol. 2002;283:G1051–61.

10.

Garcia-Trevijano ER, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, Covarrublas-Pinedo A, et al. Transforming growth factor β1 induces the expression of α1(I) procollagen mRNA by a hydrogen peroxide-C/EBPβ-dependent mechanism in rat hepatic stellate cells. Hepatology. 1999;13:1193–202.

11.

Chang L, Karin M. Mammmalian MAP kinase signaling cascades. Nature. 2001;410:37–40.PubMedCrossRef

12.

Anania FA, Womack L, Jiang M, Saxena NK. Aldehydes potentiate α2(I)collagen gene activity by JNK in hepatic stellate cells. Free Radic Biol Med. 2001;30:846–57.PubMedCrossRef

13.

Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005;54:142–51.PubMedCrossRef

14.

Boudreau HE, Emerson SU, Korzeniowska A, Jendrysik MA, Leto TL. Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor β-dependent manner: a new contributor to HCV-induced oxidative stress. J Virol. 2009;83:12934–46.PubMedCrossRef

15.

de Mochel NSR, Seronello S, Wang SH, Ito C, Zheng JX, Liang TJ, Lambeth JD, Choi J. Hepatocyte NAD(P)H oxidase as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology. 2010;52:47–59.PubMedCrossRef

16.

Liu SX, Athar M, Lippai I, Waldren TC, Hey TK. Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci USA. 2001;98:1643–8.PubMedCrossRef

17.

Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh S, et al. Role of reactive oxygen species in TGFβ-1-induced mitogen-activated protein activation and epithelial–mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol. 2005;16:667–75.PubMedCrossRef

18.

Reeves HL, Dack CL, Peak M, Burt AD, Day CP. Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. J Hepatol. 2000;32:465–72.PubMedCrossRef

19.

Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, Aoyama T. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARα-null mice through attenuation of increases in oxidative stress. J Hepatol. 2009;50:1236–46.PubMedCrossRef

20.

Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res. 2005;34:65–73.PubMedCrossRef

21.

Tsuchiya H, Akechi Y, Ikeda R, Hoshikawa Y, Kurimasa A, Shiota G. Suppressive effects of retinoids on iron-induced oxidative stress in the liver. Gastroenterology. 2009;136:341–50.PubMedCrossRef

Title: Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor β1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation
Authors: Remina Ikeda
Kyoko Ishii
Yoshiko Hoshikawa
Junya Azumi
Yuta Arakaki
Toshihiro Yasui
Shizuka Matsuura
Yoshiaki Matsumi
Yohei Kono
Yusuke Mizuta
Akihiro Kurimasa
Ichiro Hisatome
Scott L. Friedman
Hironaka Kawasaki
Goshi Shiota
Publication date: 01-06-2011
Publisher: SP Birkhäuser Verlag Basel
Published in: Inflammation Research / Issue 6/2011
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-011-0309-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective and design

Material

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2011

Comparison of cardioprotective and anti-inflammatory effects of ischemia pre- and postconditioning in rats with myocardial ischemia–reperfusion injury

Anti-inflammatory effects of ivermectin in mouse model of allergic asthma

Adjuvant arthritis influences expression of housekeeping genes

SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts

Tumor necrosis factor-α induces expression and release of interleukin-6 by human urothelial cells

Effects of endogenous substance P expression on degranulation in RBL-2H3 cells

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials